# Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001

> **NCT02655601** · PHASE1,PHASE2 · COMPLETED · sponsor: **BioMimetix JV, LLC** · enrollment: 177 (actual)

## Conditions studied

- High Grade Glioma
- Astrocytoma, Grade III
- Glioblastoma

## Interventions

- **DRUG:** BMX-001
- **RADIATION:** Radiation Therapy
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT02655601
- **Lead sponsor:** BioMimetix JV, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-25
- **Primary completion:** 2023-08-17
- **Final completion:** 2024-12-31
- **Target enrollment:** 177 (ACTUAL)
- **Last updated:** 2025-06-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02655601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02655601, "Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02655601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*